- Home
- XENE
as 11-14-2024 2:38pm EST
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 3.0B | IPO Year: | 2014 |
| Target Price: | $57.30 | AVG Volume (30 days): | 367.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.10 - $50.99 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1600.08% |
Latest Xenon Pharmaceuticals Inc. News
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Xenon to Present at Upcoming Investor Conferences
Zacks
a day ago
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
GuruFocus.com
2 days ago
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
MT Newswires
2 days ago
Xenon Pharmaceuticals Q3 Net Loss Widens
Associated Press Finance
2 days ago
Xenon Pharmaceuticals: Q3 Earnings Snapshot
GlobeNewswire
2 days ago
Xenon Reports Q3 2024 Financial Results and Business Update
GuruFocus.com
4 days ago
Earnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2024 Result
GlobeNewswire
9 days ago
Xenon to Report Q3 2024 Financial Results on November 12, 2024
Compare XENE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.